“Bimekizumab Cumulative Clinical Benefit in Patients With Moderate to Severe Hidradenitis Suppurativa through 1 Year of the BE HEARD I&II Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s477, https://doi.org/10.25251/skin.8.supp.477.